{"disease":{"id":"upper-tract-urothelial-cancer","name":"upper tract urothelial cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05810623","title":"Single-Dose Intravesical Chemotherapy After Diagnostic URS","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":394,"lead_sponsor_name":"David D'Andrea","has_results":false},{"nct_id":"NCT05438537","title":"A Comprehensive Prospective Assessment of the Physical and Biological Effects of Upper Tract Urothelial Cancer (UTUC)","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT06820255","title":"DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":135,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04197986","title":"Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":39,"lead_sponsor_name":"QED Therapeutics, a BridgeBio company","has_results":true},{"nct_id":"NCT06822010","title":"SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT06987552","title":"Single-Port RAS Using Da Vinci SP Surgical System for UTUC Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}